Century Therapeutics Inc

NASDAQ:IPSC   3:59:54 PM EDT
9.54
+0.05 (+0.53%)
Products

Century Therapeutics Receives Study May Proceed Notification From FDA For CNTY-101 To Overcome Three Major Pathways Of Host Versus Graft Rejection

Published: 08/25/2022 11:59 GMT
Century Therapeutics Inc (IPSC) - Century Therapeutics Receives Study May Proceed Notification From FDA for Cnty-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host Versus Graft Rejection.
Century Therapeutics - Investigational New Drug Application for Cnty-101, Cleared by FDA.
Century Therapeutics - Phase 1 Elipse-1 Trial Evaluating Cnty-101 in Relapsed/refractory Cd19 Positive B-cell Malignancies Anticipated to Begin in 2h22.